Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Large B-Cell, Diffuse 18Lymphoma, Non-Hodgkin 17Neuroblastoma 16Leukemia, Myeloid, Acute 14Leukemia 13Hodgkin Disease 13Central Nervous System Neoplasms 13Small Cell Lung Carcinoma 10Sarcoma 9Brain Neoplasms 9Recurrence 8Medulloblastoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Rhabdoid Tumor 7Multiple Myeloma 7Lymphoma, B-Cell 7Lung Neoplasms 7Burkitt Lymphoma 7Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 6Astrocytoma 6Teratoma 5Ovarian Neoplasms 5Neoplasms, Germ Cell and Embryonal 5Neoplasms 5Glioma 5

Interventions

Rituximab 12Cyclophosphamide 12fludarabine 8dacetuzumab 7blinatumomab 6Tacrolimus 6Busulfan 6Vincristine 5Prednisone 5Etoposide 5Doxorubicin 5Bortezomib 5fludarabine phosphate 4Valganciclovir 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Epoetin Alfa 4venetoclax 3ibrutinib 3Whole-Body Irradiation 3Methotrexate 3Melphalan 3Lenalidomide 3Ganciclovir 3Everolimus 3Dexamethasone 3Darbepoetin alfa 3Alemtuzumab 3tetulomab tetraxetan lu-177 2ponatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × etoposide phosphate × Clear all
NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Columbia University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡